AI-generated summary
The authors report on six patients with cancer who developed facial acneiform rash from cetuximab and were treated with high-level laser therapy over four days. They report a noteworthy decrease in rash toxicity and discomfort scores, with complete regression of lesions by the end of follow-up in all treated areas. The study was a small original report without a control group, so the findings are preliminary.
- Who or what was studied
- Six patients with cancer on cetuximab: four with metastatic colorectal cancer and two with head and neck cancer, each showing facial acneiform rash.
- Limits stated in the abstract
- The abstract describes only six patients, with no control group, so the reported effectiveness is preliminary and cannot be generalized.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.